These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33465279)

  • 21. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
    Korczowski B; Antadze T; Giorgobiani M; Stryjewski ME; Jandourek A; Smith A; O'Neal T; Bradley JS
    Pediatr Infect Dis J; 2016 Aug; 35(8):e239-47. PubMed ID: 27164462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
    Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M
    Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.
    Riccobene TA; Pushkin R; Jandourek A; Knebel W; Khariton T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5849-57. PubMed ID: 27431215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.
    Justo JA; Mayer SM; Pai MP; Soriano MM; Danziger LH; Novak RM; Rodvold KA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3956-65. PubMed ID: 25896707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetics and pharmacodynamics of ceftaroline].
    Grau S; Sorlí L; Luque S
    Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():15-20. PubMed ID: 24702974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
    Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
    Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume.
    Edeki T; Kujacic M; Broadhurst H; Li J; Sunzel M
    Br J Clin Pharmacol; 2014 Dec; 78(6):1291-7. PubMed ID: 25041494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects.
    Riccobene TA; Su SF; Rank D
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1496-504. PubMed ID: 23295928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
    Bhavnani SM; Hammel JP; Van Wart SA; Rubino CM; Reynolds DK; Forrest A; Drusano GL; Khariton T; Friedland HD; Riccobene TA; Ambrose PG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):372-80. PubMed ID: 25367904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis.
    Bradley JS; Stone GG; Chan PLS; Raber SR; Riccobene T; Mas Casullo V; Yan JL; Hendrick VM; Hammond J; Leister-Tebbe HK
    Pediatr Infect Dis J; 2020 May; 39(5):411-418. PubMed ID: 32091493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin.
    van Os W; Pham AD; Eberl S; Minichmayr IK; van Hasselt JGC; Zeitlinger M
    Int J Antimicrob Agents; 2024 May; 63(5):107148. PubMed ID: 38508535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
    Bhalodi AA; Crandon JL; Biek D; Nicolau DP
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6160-5. PubMed ID: 22985880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an
    Werth BJ; Shireman LM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.